Evaluation of Anti-Infectious Activity of Bioconjugates Based on Quantum Dots CdTe / Cd MPA 710 and Levofloxacin against Staphylococcal Corneal Infection. Experimental Research

Infectious keratitis is one of the leading causes of persistent decline in visual function and monocular blindness in both developed and developing countries. The combination of factors in the prevalence of eye infectious and inflammatory diseases, antibiotic resistance, and internal mutations of the pathogens themselves exacerbate the need to search for highly effective alternatives in the fight against eye infectious diseases. Of particular interest are the prospects for the use of fluorescent semiconductor nanocrystals, called quantum dots, in the treatment of resistant infectious inflammatory diseases. The objective of the study was to assess the anti-infectious activity of bioconjugates based on CdTe / Cd MPA 710 quantum dots and levofloxacin against staphylococcal corneal infection using the example induced infectious keratitis in laboratory animals. As the object of the study, 6 male (6 eyes) New Zealand rabbits were studied, which underwent induction of bacterial keratitis by introducing a hospital strain of S. Aureus into the structure of the cornea. The following were used as antimicrobial agents: a solution of levofloxacin 5 ml for epibulbar use and a bioconjugate based on CT CdTe / Cd MPA 710 and levofloxacin.

1. Flaxman S.R., Bourne R.R.A., Resnikoff S. Global causes of blindness and distancvision impairment 1990 2020: a systematic review and meta analysis. Lancet Glob Health. 2017; 5: 1221–1234. DOI: 10.1016/S2214-109X(17)30393-5

2. Ting D.S.J., Ho C.S., Cairns J. 12 year analysis of incidence, microbiological profiles and in vitro antimicrobial susceptibility of infectious keratitis: the Nottingham Infectious Keratitis Study. Br J Ophthalmol. 2020;105:328–333. DOI: 10.1136/bjoph-thalmol-2020-316128

3. Khor W.B., Prajna V.N., Garg P. The Asia Cornea Society Infectious Keratitis Study: a Prospective Multicenter Study of Infectious Keratitis in Asia. Am J Ophthalmol. 2018;195:161–170. DOI: 10.1016/j.ajo.2018.07.040

4. Ting D.S., Shan Ho C., Deshmukh R. Infectious keratitis: an update on epidemiology, causative microorganisms, risk factors, and antimicrobial resistance. Nature (Eye). 2021;35:1084–1101. DOI: 10.1038/s41433-020-01339-3

5. Sait Egrilmez S., Yildirim Theveny S. Treatment Resistant Bacterial Keratitis: Challenges and Solutions. Clin Ophthalmol. 2020;14:287–297. DOI: 10.2147/OPTH.S181997

6. Silvester A., Neal T., Czanner G. Adult bacterial conjunctivitis: resistance patterns over 12 years in patients attending a large primary eye care centre in the UK. BMJ Open Ophthalmol. 2017;1(1):e000006. DOI: 10.1136/bmjophth-2016-000006

7. Friling E., Montan P. Bacteriology and cefuroxime resistance in endophthalmitis following cataract surgery before and after the introduction of prophylactic intracameral cefuroxime: a retrospective single centre study. J Hosp Infect. 2019;101(1):88–92. DOI: 10.1016/j.jhin.2018.02.005

8. Read A.F., Woods R.J. Antibiotic resistance management. Evol. Med. Public Health. 2014;14(1):147. DOI: 10.1093/emph/eou024

9. Bartlett J.G., Gilbert D.N., Spellberg B. Seven ways to preserve the miracle of antibiotics. Clin. Infect. Dis. 2013;56(10):1445–1450. DOI: 10.1093/cid/cit070

10. Viswanathan V.K. Off label abuse of antibiotics by bacteria. Gut. Microbes. 2014;5(1):3–4. DOI: 10.4161/gmic.28027

11. Luyt C.E., Brechot N., Trouillet J.L., Chastre J. Antibiotic stewardship in the intensive care unit. Crit. Care. 2014;18(5):480. DOI: 10.1186/s13054-014-0480-6

12. Ponomarev V.O., Kazaykin V.N., Lizunov A.V. , Vokhmintsev A.S., Vainshtein I.A., Dezhurov S.V. Evaluation of the ophthalmotoxic effect of quantum dots and biocon jugates based on them in terms of the prospects for the treatment of resistant endophthalmitis. Experimental research (stage 1). Ophthalmology in Russia. 2021;18(3): 476–487 (in Russ.) https://doi.org/10.18008/1816-5095-2021-3-476-487

13. Goodman M., Levy M., Fei Fei L. Designing Superoxide Generating Quantum Dots for Selective Light Activated Nanotherapy. Front. Chem. 2018;46(6):1–12. DOI: 10.3389/fchem.2018.00046